Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Continuing Forward With Innovation and Progress in US Healthcare
May 22, 2017
Dr Gail Wilensky: Senate Health Bill Will Be to the Left of the House
May 22, 2017
Accounting for Stakeholder Preferences in Value Assessments
May 22, 2017
Dr David M. Cutler Highlights the Importance of Reauthorizing the CHIP Program
May 22, 2017
Negotiating Successful Outcomes-Based Contracts
May 23, 2017
Dr Ilene Hollin: Tailored Approach to Value Assessment Is Necessary
May 23, 2017
Influencing Untreated Individuals Through Their Social Networks
May 23, 2017
Dr Steve Pearson Outlines the Importance of Thresholds on Determining Value
May 23, 2017
The Realities and Challenges of Medicare Negotiating Drug Prices
May 24, 2017
Dr Patricia Danzon: Cost-Effectiveness Thresholds Create Incentive to Develop Better Drugs
May 24, 2017
Gene Therapies Present Great Potential, but Also Ethical and Practicality Challenges
May 24, 2017
Dr James D. Chambers Talks Future Health Economics Trends He Is Watching
May 24, 2017
Dr Gail Wilensky Remains "Hopeful" for Bipartisan Legislation on Healthcare Reform
May 29, 2017
Dr David Cutler: Won't Be Easy for Senate Republicans to Create a Healthcare Bill
May 30, 2017
Not Enough Attention Paid to Low Healthcare Spending Growth
June 13, 2017
Currently Reading
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017

Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework

As the Institute for Clinical and Economic Review (ICER) prepares to update its final value proposal framework, it has been aided by the constructive comments from different stakeholders, said ICER president Steve Pearson, MD, MSc. He predicts that coming years will see continued interest in how to utilize such frameworks.


As the Institute for Clinical and Economic Review (ICER) prepares to update its final value proposal framework, it has been aided by the constructive comments from different stakeholders, said ICER president Steve Pearson, MD, MSc. He predicts that coming years will see continued interest in how to utilize such frameworks.

Transcript (slightly modified)

How does ICER plan to update its value framework?

ICER has gone through a fairly long process now of getting public comment in 2 separate phases on our value framework, and we’ve actually received tremendously helpful suggestions in both phases. It’s taken us longer than we thought to get through the second phase, so we’ve been a bit delayed in announcing our final update proposals, but that should come out now within the next few weeks.

We’re really looking forward to continuing to work with stakeholders, because we learn as they learn as we continue to work together on these reports and as we go together to these public meetings. There will be further work to be done together, but we’re very exciting about putting out our update proposals and moving forward with the stakeholder groups.

What has been the uptake and use of value frameworks?

The growth of the use, if you will, the downloads have been going up and up. We hear a lot of anecdotal evidence, and there have been some surveys on the number of payers that are using our research to support both coverage decisions but also considerations around pricing and payment models.

I do think that there’s going to be continued interest in trying to figure out how to use value frameworks going forward. The value frameworks that are out there have very different histories, but also very different purposes, and so they’re kind of structured differently to meet those different goals. I think people are gaining more awareness of the reason that value frameworks don’t all look the same, because they have different functions, if you will.

I do think that a general purpose of trying to make as clear as possible and as fair as possible an approach to judging value is something that our health system really needs.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up